Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.42 CAD | -2.33% | -10.64% | -14.29% |
May. 08 | Crescita Therapeutics Q1 Loss Widens, Revenue Rises | MT |
May. 08 | Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million | MT |
Sales 2022 | 23.52M 17.22M | Sales 2023 | 17.52M 12.83M | Capitalization | 9.79M 7.17M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -1M -732K | EV / Sales 2022 | 0.29 x |
Net cash position 2022 | 6.7M 4.9M | Net cash position 2023 | 8.13M 5.96M | EV / Sales 2023 | 0.09 x |
P/E ratio 2022 |
16.5
x | P/E ratio 2023 |
-4.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.57% |
1 day | -2.33% | ||
1 week | -10.64% | ||
Current month | -2.33% | ||
1 month | -2.33% | ||
6 months | +9.09% | ||
Current year | -14.29% |
Managers | Title | Age | Since |
---|---|---|---|
Serge Verreault
CEO | Chief Executive Officer | - | - |
Jose DaRocha
DFI | Director of Finance/CFO | - | 17-08-31 |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 16-02-29 | |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
John London
BRD | Director/Board Member | - | 16-02-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-27 | 0.42 | -2.33% | 34,065 |
24-05-24 | 0.43 | -8.51% | 5,661 |
24-05-23 | 0.47 | 0.00% | 5,500 |
24-05-22 | 0.47 | 0.00% | 500 |
Delayed Quote Toronto S.E., May 27, 2024 at 03:22 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-14.29% | 5.99M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.15% | 238B | |
+7.05% | 204B | |
-6.50% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- CTX Stock